X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
elbasvir (98) 98
index medicus (95) 95
hepatitis c virus (81) 81
grazoprevir (76) 76
hepatitis c (75) 75
ribavirin (68) 68
humans (64) 64
treatment-naive (56) 56
hepatitis (54) 54
gastroenterology & hepatology (52) 52
sofosbuvir (45) 45
elbasvir mk-8742 (44) 44
hcv (42) 42
antiviral agents - therapeutic use (38) 38
grazoprevir mk-5172 (38) 38
infections (38) 38
interferon (38) 38
pharmacology & pharmacy (38) 38
hepatitis c, chronic - drug therapy (35) 35
antiviral agents (34) 34
hepatitis-c virus (34) 34
safety (33) 33
health aspects (32) 32
efficacy (31) 31
genotype 1 infection (31) 31
combination therapy (30) 30
genotypes (30) 30
infectious diseases (30) 30
treatment-experienced patients (29) 29
virus diseases (28) 28
male (27) 27
genotype (26) 26
hepacivirus - drug effects (25) 25
hepacivirus - genetics (25) 25
infection (25) 25
patients (25) 25
cirrhosis (24) 24
hepatitis c - drug therapy (24) 24
mk-5172 (24) 24
antiviral agents - administration & dosage (23) 23
combination (23) 23
elbasvir/grazoprevir (23) 23
female (23) 23
clinical trials (22) 22
genotype & phenotype (22) 22
imidazoles - therapeutic use (22) 22
ledipasvir (22) 22
quinoxalines - therapeutic use (22) 22
adult (21) 21
benzofurans - therapeutic use (21) 21
drug therapy (21) 21
middle aged (21) 21
virus genotype 1 (21) 21
analysis (19) 19
mk-8742 (19) 19
therapy (19) 19
viruses (19) 19
drug therapy, combination (18) 18
human immunodeficiency virus--hiv (18) 18
treatment outcome (18) 18
virology (18) 18
antiviral agents - adverse effects (17) 17
chronic infection (17) 17
coinfection (17) 17
drug combinations (17) 17
genetic aspects (17) 17
genotype 1 (17) 17
label phase-2 trial (17) 17
liver (17) 17
open-label (17) 17
benzofurans - administration & dosage (16) 16
hcv ns5a inhibitor (16) 16
imidazoles - administration & dosage (16) 16
quinoxalines - administration & dosage (16) 16
aged (15) 15
antiviral agents - pharmacology (15) 15
digestive system diseases (15) 15
hepatitis c, chronic - virology (15) 15
care and treatment (14) 14
daclatasvir (14) 14
hiv (14) 14
microbiology (14) 14
ombitasvir (14) 14
sustained virological response (14) 14
treatment-naive patients (14) 14
viral nonstructural proteins - antagonists & inhibitors (14) 14
antiviral agents - pharmacokinetics (13) 13
drug interactions (13) 13
hepatology (13) 13
liver cirrhosis (13) 13
medical research (13) 13
ns3/4a protease (13) 13
antiretroviral drugs (12) 12
benzofurans - pharmacokinetics (12) 12
dasabuvir (12) 12
hiv infections - complications (12) 12
imidazoles - adverse effects (12) 12
imidazoles - pharmacokinetics (12) 12
pegylated interferon (12) 12
quinoxalines - adverse effects (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 24, pp. 2394 - 2395
An open-label pilot trial involving 10 patients shows that hepatitis C virus genotype 1–infected kidneys transplanted into HCV-negative recipients, followed by... 
MEDICINE, GENERAL & INTERNAL | VIRUS GENOTYPE 1 | TREATMENT-NAIVE | ELBASVIR | Hepacivirus - isolation & purification | Pilot Projects | Humans | Middle Aged | Hepatitis C - virology | Hepacivirus - genetics | RNA, Viral - analysis | Adult | Kidney Transplantation | Kidney - virology | Viral Load
Journal Article
HEPATOLOGY, ISSN 0270-9139, 02/2017, Volume 65, Issue 2, pp. 439 - 450
Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different... 
PROTEASE INHIBITOR | NS5A INHIBITOR | TREATMENT-NAIVE | CHRONIC HCV | NONCIRRHOTIC PATIENTS | COMBINATION THERAPY | GRAZOPREVIR | ELBASVIR | VIRUS GENOTYPE 1 | GASTROENTEROLOGY & HEPATOLOGY | VIROLOGICAL RESPONSE
Journal Article
Annals of Hepatology, ISSN 1665-2681, 01/2019, Volume 18, Issue 1, pp. 236 - 239
Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens... 
Treatment failure | Hepatitis C virus | Genotype 3 | Grazoprevir + elbasvir | Sofosbuvir | 3 INFECTION | Grazoprevir plus Elbasvir | GASTROENTEROLOGY & HEPATOLOGY | HEPATITIS-C
Journal Article
Journal of the Formosan Medical Association, ISSN 0929-6646, 10/2019
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 11/2019, p. 112964
Journal Article
TRANSPLANTATION, ISSN 0041-1337, 05/2017, Volume 101, Issue 5, pp. 974 - 979
Background Ledipasvir-sofosbuvir is effective at eradicating hepatitis C virus (HCV) infection in the general population and in HCV-monoinfected kidney... 
SURGERY | TREATMENT-NAIVE | THERAPY | ELBASVIR | SIMEPREVIR | VIRUS GENOTYPE 1 | INFECTION | HCV | RIBAVIRIN | IMMUNOLOGY | TRANSPLANTATION
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 09/2018, Volume 169, Issue 5, pp. 273 - 281
Background: Organs from hepatitis C virus (HCV)-infected deceased donors are often discarded. Preliminary data from 2 small trials, including THINKER-1... 
MEDICINE, GENERAL & INTERNAL | VELPATASVIR | CONFIDENCE-INTERVALS | TREATMENT-NAIVE | SOFOSBUVIR | DISEASE | ELBASVIR | VIRUS GENOTYPE 1 | HCV | DONORS | QUALITY-OF-LIFE | Treatment outcome | Usage | Kidneys | Analysis | Clinical trials | Transplantation | Quality of life
Journal Article
Journal Article
20.